NEWS

Hyleukin-7^TM Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA^®

NeoImmuneTech Announces Initiation of Hyleukin-7^TM Clinical Development for Cancer Patients in the U.S.

NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7^TM in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers